Date: 2017-02-09
Type of information: Nomination
Compound: member of the board of directors
Company: Molecular Partners (Switzerland)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On February 9, 2017. Molecular Partners announced that the Board of Directors has decided to propose Gwen Fyfe, MD, for election as member of the board of directors at the next Annual General Meeting on May 11, 2017. Last November, Christian Zahnd, Ph.D., co-founder and Chief Executive Officer (CEO) of the company, announced his resignation due to health reasons.
Gwen Fyfe has more than 20 years of drug development experience in oncology. She held various positions at Genentech from 1997-2009, including vice president, oncology development, playing an important role in the development of Genentech’s approved oncology agents including Rituxan®, Herceptin®, Avastin® and Tarceva®. Since leaving Genentech in 2009, she has been a consultant for venture capital firms and for a variety of biotechnology companies. Gwen is a recognized expert in the broader oncology community and has been an invited member of Institute of Medicine panels, National Cancer Institute working groups and grant committees and American Society of Clinical Oncologists oversight committees. She is a graduate of Washington University School of Medicine and a board certified pediatric oncologist.
Financial terms:
Latest news:
Is general: Yes
